Laughing Water Capital’s New Position: Theravance Biopharma (TBPH)
Laughing Water Capital, an investment management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Theravance Biopharma Inc. (TBPH)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Madison Avenue Partners Eli Samaha | 9,212,252 | $156,608,284 | -4% | 6.74% |
| 2. | Weiss Asset Management Andrew Weiss | 7,457,060 | $126,770,020 | 1.33% | |
| 3. | Newtyn Management Noah Levy And Eugene Dozortsev | 3,434,191 | $58,381,247 | -30% | 7.29% |
| 4. | Irenic Capital Management Adam Katz And Andy Dodge | 2,760,948 | $46,936,116 | 2.25% | |
| 5. | D E Shaw D. E. Shaw | 1,185,390 | $20,151,630 | +25% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.80 | 999,800 | $7,798,440.00 | 9,511,150 | 2024-08-07 | Filing | |
| $8.75 | 499,324 | $4,369,085.00 | 8,511,350 | 2024-05-01 | Filing | |
| $8.75 | 999,800 | $8,748,250.00 | 8,012,026 | 2024-05-01 | Filing | |
| $22.54 | 1,000 | $22,540.00 | 56,757 | 2018-05-21 | Filing | |
| $26.34 | 4,000 | $105,358.80 | 213,180 | 2017-08-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.17 | 5,564 | $95,540.56 | 9,167,489 | 2026-07-07 | Filing | |
| $17.04 | 1,400 | $23,856.00 | 9,173,053 | 2026-07-06 | Filing | |
| $17.00 | 37,799 | $642,628.36 | 9,174,453 | 2026-07-01 | Filing | |
| $17.13 | 25,027 | $428,787.59 | 9,212,252 | 2026-06-30 | Filing | |
| $17.23 | 273,871 | $4,720,139.30 | 9,237,279 | 2026-06-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,562,487 | $77,562,279 | 0% | |
| 2. | 1,771,493 | $30,115,381 | 0% | |
| 3. | 1,328,584 | $22,585,928 | 0% | |
| 4. | 1,117,895 | $19,006,198 | 0% | |
| 5. | 1,043,051 | $17,732,125 | 0% |
News See All
B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14
Theravance Biopharma, Inc. (NASDAQ:TBPH) is one of the most undervalued biotech stocks to buy right now. B. Riley lifted the price target on Theravance Biopharma, Inc.
8 Most Undervalued Biotech Stocks to Buy Right Now
On April 13, Tom Lee, Fundstrat's head of research, appeared on CNBC’s 'Power Lunch' to talk about his outlook on equities, what to expect in a wartime economy, and more.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Third Quarter 2025 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Second Quarter 2025 Conference Call.
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma
Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript
Operator: Hello, ladies and gentlemen. Good afternoon. I would like to welcome everyone to the Theravance Biopharma First Quarter 2025 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript February 26, 2025Theravance Biopharma, Inc. misses on earnings expectations.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I would like to welcome everyone to the Theravance Biopharma Third Quarter 2024 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript August 5, 2024Theravance Biopharma, Inc. misses on earnings expectations.